Purpose: e aim of this study was to evaluate the e ects of pomegranate (PMG) extract and carvacrol (CARV) on methotrexate (MTX)-induced oxidative stress and bone marrow toxicity.
Methotrexate (MTX) is a folic acid (FA) antagonist and chemotherapeutic agent in tumor treatment and is one of the most commonly used antimetabolite agents for childhood cancers. It is also used for the treatment of in ammatory diseases such as idiopathic juvenile arthritis, psoriasis and dermatomyositis [1] [2] [3] [4] . MTX decreases the production of rheumatoid factor and the interaction between leukocytes. It can be used at an intermittent low dose for the treatment of refractory rheumatic diseases [5] and also for the treatment of ectopic pregnancy [6, 7] .
MTX restricts thymidylate synthesis and, ultimately, purine and pyrimidine nucleotides (the building blocks of DNA and RNA) by inhibiting the dihydrofolate reductase enzyme that converts dihydrofolate to tetrahydrofolate [8, 9] . Both therapeutic and toxic e ects of MTX have emerged as a result of the changes made by MTX on many metabolic pathways, including DNA synthesis [10] . In addition, MTX treatment is known to cause bone marrow toxicity [11] .
Punica granatum, commonly known as pomegranate (PMG), is a fruit that grows in tropical and subtropical areas.
e juice extract of PMG contains approximately 40% ellagic acid [12] . Ellagic acid is a polyphenol compound with antioxidant and anti-proliferative properties that also exists in many other fruits and plants such as raspberries, pecan nuts and strawberries.
ese components demonstrate anti-in ammatory and antioxidant e ects by inhibiting the expression of pro-in ammatory enzymes and cytokines [13, 14] . e anticarcinogenic [15] , antioxidant [16, 17] , anti-in ammatory [18] , antimicrobial [19, 20] , antihypertensive and angiogenic e ects of PMG extract are well established.
Carvacrol (CARV) is a common ingredient found in the widely used herb, oregano. Oregano is generally accepted as a safe food [21, 22] . Many di erent features and e ects have been reported for oregano, which has been used for epidemics since ancient times, as a result of contemporary studies. In animal experiments, it was observed that CARV extract from oregano has anti-in ammatory [23] , antimicrobial [24] , antitumor, anti-spasmolytic [25, 26] and antioxidant [28] properties. In addition, it was reported that it had a protective e ect against liver injury [27] .
Oxidative stress causes cellular damage as a result of the imbalance between reactive oxygen species and the biological ability of the cell to repair damage or detoxify oxidants [29] . Malondialdehyde (MDA) is an important product of lipid peroxidation and results in some adverse e ects, such as ion permeability and change of enzyme activity, by acting on ion exchange through cell membranes. It has been reported that an increase in MDA levels correlates with an increase in free oxygen radicals in a tissue [30] . In the measurement of oxidative stress, it can be di cult to pinpoint speci c oxidants, because an individual measurement for each antioxidant within a biological sample is required. Measurement of total antioxidant capacity (TAC) is useful if one wants to demonstrate total changes in antioxidant status within speci c samples [31] ; therefore, the measurement of TAC may be an important and useful tool in the prevention of methotrexate-induced oxidative damage/toxicity.
ere have been an increasing number of studies about the antioxidant protection of PMG and CARV. is research is the rst in vi o study investigating the e ects of PMG and CARV against the toxicity of MTX on bone marrow in rats. e aim of this study was to investigate whether the adverse e ects of MTX can be prevented by these natural molecules.
Materials and Methods
e e ects of PMG and CARV on bone marrow toxicity in rats treated with MTX were compared. Animals e study protocol was approved by Dicle University Faculty of Medicine, Local Ethics Committee for Animal Experiments. Wistar albino rats were obtained from Dicle University Central Animal House. Male Wistar Albino rats, 8-12 weeks of age with an average weight of 250 grams, were used. Animals were kept under an appropriate moisture, lighting (12 hours of daylight/12 hours of dark) and heat (21 ± 2 ºC). Animals were fed standard rat chow and tap water. A wire litter was placed in the cage in order to prevent coprophagy.
Experimental Protocol
Experimental animals (32 rats) were divided randomly into four groups: control, methotrexate (MTX), MTX+CARV, and MTX+PMG groups. e study protocol is summarized in Table 1 .
Group 1 (Control): As a basic control group, rats were not given any drug. Normal feeding was provided.
Group 2 (MTX): On the second day methotrexate (MTX, Onco-Tain, Faulding Pharmaceutics Pic, UK) 20 mg/ kg was given intraperitoneally. Rats were fed with normal food for seven days.
Group 3 (MTX+CARV): A 73 mg/kg dose of oregano oil containing 83% CARV was injected intraperitoneally on the rst day, followed by a 20 mg/kg dose of MTX injected intraperitoneally on the second day. e plant substance tested in this study, CARV (2-methyl-5-(1-methylethyl)-phenol), was isolated from steam distillated essential oil of Origanum onites L.
collected from West Anatolia as described by Canbek et al. [32] .
Group 4 (MTX+PMG): 225 mg/kg pomegranate extract (Pomella®, Verdure Sciences, Noblesville, IN, USA; 250 mg/ kg/day) was administered orogastrically (with a gavage needle) once each day beginning on the rst day and continuing for seven days. Twenty mg/kg of MTX was given intraperitoneally on the second day.
No animal died during the experiment. To obtain blood and bone marrow samples, the animals were sacri ced with general anesthesia: 1 mg/kg xylazine (Rompun®; Bayer AG, Leverkusen, Germany) + 0.5 ml/kg ketamine was injected intraperitoneally for general anesthesia.
Hematology
Blood samples were extracted intracardially for hematological and biochemical tests into separate tubes by opening the abdomen with a median line incision. Heparinized blood samples were used for hematological analysis. e hematological parameters hematocrit (Hct), hemoglobin (Hb), red blood cell count (RBC), total white blood cell count (WBC), mean corpuscular volume (MCV), platelets (PLT) and lymphocytes were measured by automated cell counter (Abbott CELL DYN 3700 model device).
e femur was cropped and the bone marrow cavity was accessed with a needle. Bone marrow samples obtained from the femur were stained using May-Grünwald and Giemsa stainings. Bone marrow aspirates from the femur of each animal were assessed histologically to assess granulocytic cell lineage, erythroid cell lineage, presence of megakaryocyte and density of adipocytes. Microscopic scoring was done by an experienced histologist (Dr. S.S.) blinded to the animal groups. Histological slides were examined with a light microscopic using magni cations of 41, 82 and 164 times . Arbitrary areas were chosen for assessing cell densities. en count of cell and density of adipocytes per each 10×40 ampli cation areas (one 10x40 magnication microscopic area was 0.19 mm 2 ) were determined. e average values of ve adjacent microscope areas were found, and then cell count and density of adipocytes per 1 mm 2 were calculated. Bone marrow cellularity scoring was accepted as follows; (4 points) cell count between 80% and 100%, (3 points) cell count between 60% and 80%, (2 points) cell count between 40% and 60%, and (1 point) count of cells <40%. Density of adipocytes in the bone marrow were scored as follows; (1 point) normal density of adipocytes, (2 points) mild (<25%), (3 points) moderate (<25%-50%) and (4 points) severe intense adipocytes (>50%).
Biochemical measurements
TAC and total oxidant status (TOS) were measured by the Erel method with an Abbott Architect c16000 (Abbott Park, North Chicago, IL, USA) chemical analyzer [31] . Determination of MDA levels was performed by HPLC based on the di erentiation with dinitrophenylhydrazine [33] .
Statistical analysis
All data are expressed as mean and standard deviation (SD). A one-sample Kolmogorov-Smirnov test was performed in order to determine if the data was normally distributed. Intergroup comparisons were performed using the Kruskal-Wallis and Mann-Whitney U-test. P values <0.05 were considered statistically signi cant. All data were processed using the statistical package SPSS 18.0 for Windows (IBM Corporation, Armonk, NY).
Results
Signi cantly lower Hb and Hct values, and higher MCV values were detected in the rats treated with MTX (Group 2) (p<0.05-0.01; Table 2 ). e Hb and Hct values were signicantly lower in Group 2 compared with Group 3 (MTX+CARV) and Group 4 (MTX+PMG) (p<0.05) ( Table  2 ). e peripheral white blood cell counts were found to be lower in Group 2 when compared with Group 3 and Group 4 (p<0.05) ( Table 2) . Although platelet counts were lower in Group 2, they were closer to normal values in Group 3 and Group 4 ( more similar to control groups than rats treated with CARV ( Table 2) . Evaluation of bone marrow smears indicated a signi cant decrease in bone marrow cellularity in Group 2 (median 2.0, range 1.0-2.0) when compared with the control group (median 4.0, range 3.0-4.0) (p<0.001) (Fig. 1a, 1b, 1c ).
An increase in bone marrow cellularity was observed in Groups 3 (median 3.0, range 2.0-4.0) (p=0.005) and 4 (median 4.0, range 3.0-4.0) (p=0.001) when compared with Group 2. Additionally, a more signi cant increase in bone marrow cellularity was detected in Group 3 than in Group 4 (p=0.034) (Fig. 2a, 2b) .
Overall evaluation of bone marrow smears showed that side e ects of MTX treatment in rats were related to the increase in bone marrow adiposity.
e median (minimum- ; however, PMG supplementation was found to be more e ective in the suppression of bone marrow adiposity than CARV supplementation (p=0.01) (Fig. 1b, 2a, 2b) . Serum oxidative stress parameters are presented in Table 3 . Serum MDA levels were signi cantly higher in Group 2 than in Groups 3 and 4 as shown in Table 3 . Similarly, serum TOS levels were signi cantly higher in Group 2 compared with Groups 3 and 4 (Table 3) . Interestingly, TAC was detected to be signi cantly lower in Group 2 compared with Group 1 (p = 0.002; Table 3 ). TAC was determined to be signi cantly lower in the group given only MTX than in the group given MTX+CARV (p = 0.001) ( Table 3) .
Discussion
MTX, one of the FA antagonists, is commonly used with an intermittent low dose in the treatment of juvenile idiopathic arthritis [34] , autoimmune diseases [35, 36] , in ammatory myopathies [37] and panuveitis [38] . In addition, it is also used as a basic chemotherapeutic agent for childhood leukemia and for some other types of cancer. MTX a ects highly proliferative cells, and malignant cells are not speci cally targeted; thus, other cells, such as hematopoietic cells within the bone marrow, are adversely a ected [39] . Many potential side e ects have been detected in both clinical observations and experimental animal studies due to short and long term use of MTX. e aim of this study was to investigate the e ects of PMG and CARV against MTX bone marrow toxicity in experimental animals. For this reason, the hematological parameters, including cell number and percentage, and biochemical parameters, such as TAC, TOS and MDA, were evaluated. MTX was administered to rats at a dose of 20 mg/kg intraperitoneally, as de ned previously in tissue toxicity studies [40, 41] .
In recent years, there have been many studies aiming to take advantage of natural products with antioxidant activity in order to prevent tissue damage due to oxidative stress. It has been shown that foods and drinks with high levels of phenolic components reduce the risk for some diseases such as cardiovascular diseases and cancer [42] . Pomegranate is a valuable plant that contains polyphenolic components. In particular, ellagic acid is found in high concentrations in PMG and has functional and medical e ects [43] . is component has been linked to the release of antioxidant compounds and the reduction of lipid peroxidation [43] . In addition, ellagic acid displays anti-in ammatory and antioxidant e ects by inhibiting the expression of pro-in ammatory enzymes and cytokines.
To date, the complex mechanism(s) of the e ect of MTX on bone marrow toxicity has not been elucidated [4] . It has been suggested that oxidative stress is a consequential side effect of chemotherapeutic drugs [44, 45] . For this reason, the e ect of PMG and CARV on MTX bone marrow toxicity was investigated by evaluating the oxidative stress parameters MDA, TAC, and TOS [46] . Although PMG and CARV reduced the bone marrow toxicity of MTX, it is not clear whether the reduced toxicity is a result of PMG and CARV directly interfering with the folic acid antagonism or via another mechanism. A PMG-and CARV-induced reduction in oxidative stress and reduced marrow toxicity might also reduce the desired e ects of MTX therapy, though this was not determined.
In previous studies, it has been reported that MTX increases MDA levels and addition of antioxidant substances can decrease MDA levels [47] . Jahovic and colleagues demonstrated that a single 20 mg/kg intraperitoneal dose of MTX signi cantly increases blood MDA levels in rats [48] . In our study, increased serum MDA levels in the MTX group compared with the control group was detected. Strikingly, the serum MDA levels were signi cantly lower in MTX+PMG and MTX+CARV groups compared with the MTX group. ese results suggest that the antioxidant properties of PMG and CARV are protective against the oxidative side e ects of MTX.
TAC and TOS are important biochemical markers for determining oxidative status. In this study, while TAC levels decreased in rats injected with MTX, TAC levels increased in the rats injected with MTX+PMG and MTX+CARV. An increase in TOS levels in rats receiving MTX, and a decrease in TOS levels in MTX+PMG and MTX+CARV rat groups, were observed; probably due to the protective e ects of PMG and CARV. Collectively, these results suggest that PMG and CARV exert a protective e ect on MTX-treated rats and may be important in the reduction of side e ects associated with the use of this chemotherapeutic agent.
Kojima and colleagues demonstrated the signi cant decrease in red serial cells in rats treated with MTX [49] . In our study, anemia due to disruption of hematopoiesis in the bone marrow in the Wistar albino rats treated with MTX was detected. Lower hemoglobin and hematocrit values and higher MCV values of MTX group may be secondary to folic acid antagonist e ect of MTX; however, with the addition of both CARV and PMG, signi cantly decreased MCV and increased hemoglobin and hematocrit levels were observed (Table 2 ). In addition, it was also observed that the number of red blood cells was higher in rats with MTX+CARV and MTX+PMG than in the rats treated only with MTX. ese anti-anemic e ects of CARV and PMG supplementation indicate that CARV and PMG may antagonize folic acid inhibitor e ects of MTX.
In a study conducted by McEwen and colleagues, it was reported that MTX treatment causes leukocytopenia in patients [50] . Cohen and colleagues reported that development of pancytopenia a er single dose MTX treatment [51] . In our study, MTX-treated rats also had leukocytopenia and the leukocyte count was higher in the rats treated with MTX+CARV and MTX+PMG than in the rats treated with only MTX. Çetiner and colleagues linked the toxic e ect of MTX on neu-trophils and lymphocytes to oxidative tissue damage [40] . Based on this, PMG and CARV appears to decrease the oxidative damage and help to protect the number and percentage of white blood cells. Murakami and colleagues reported that they obtained both thrombocytopenia and thrombocytosis in rats treated with MTX [52] . It was demonstrated in our study, as well as in other previous studies, that MTX causes thrombocytopenia. More importantly, it was observed that PMG and CARV supplementation was e ective in preventing thrombocytopenia.
It has been reported that MTX a ects hematopoiesis in both erythroid and myeloid cells lineages [50] . Consistent with this observation, our study showed a signi cant decrease in bone marrow cellularity in rats treated with MTX. e increase in bone marrow cellularity in the group with MTX+ PMG was determined to be more signi cant than the group with MTX+ CARV (Fig. 1b, 1c, 2a, 2b ).
Xian and colleagues reported in their recent studies that fat-containing cells increase in bone marrow in rats injected with MTX, and thus bone marrow adiposity increases [53, 54] . In this study, only MTX treatment increased the bone marrow adiposity, and MTX+PMG treatment was more e ective in suppression of bone marrow adiposity than MTX+CARV treatment.
In this study, the MTX-related toxicity was assessed but not the MTX-related therapeutic e ects; thus, it is not known whether the PMG and CARV interventions would reduce the e ectiveness of treatment with MTX.
One of the limitations of our study is the lack of an additional control group in which folinic acid was given. Folinic acid is commonly used to limit systemic action of MTX in patients receiving treatment with high dose MTX. Giving folinic acid is a strategy to augment CNS activity of MTX without causing excessive systemic toxicity. e use of a folinic acid group, as additional control group, would help to distinguish between the antioxidant activity versus rescue of the folic acid pathway.
Conclusion
e results of this study are consistent with the previously published studies presenting the adverse e ects of MTX on bone marrow. PMG and CARV can achieve protective e ects against MTX-induced toxicity and cell death, most likely due to their antioxidant properties. Interestingly, PMG was determined to be more e ective in minimizing the adverse e ects of MTX than CARV. ese two natural products may be more e ective in reducing or preventing oxidative tissue damage and toxicity caused by chemotherapeutics. Further experimental and clinical studies in this area will provide much needed insight into the protective e ects of these natural compounds against oxidative stress.
